Esclerosis múltiple recurrente remitente en el sector público de salud de Chile: Descripción clínica de 314 pacientes

2014

Abstract

Background: Immunomodulatory drugs (IMD), Interferon β1a, β1 b and glatiramer acetate are available in the Chilean public health system since June 2008 for patients with relapsing- remitting multiple sclerosis (RR-MS). Diagnostic confirmation and programmed follow up of …

Authors